Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

Conditions: Follicular Lymphoma (FL) Interventions: Drug: Epcoritamab; Drug: Prednisone; Drug: Rituximab; Drug: Lenalidomide; Drug: Doxorubicin; Drug: Vincristine; Drug: Cyclophosphamide; Drug: Obinutuzumab; Drug: Bendamustine Sponsors: AbbVie; Genmab Not yet recruiting

https://clinicaltrials.gov/study/NCT06191744

Source: ClinicalTrials.gov - January 5, 2024 Category: Research Source Type: clinical trials